PT1658269E - Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1) - Google Patents

Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1) Download PDF

Info

Publication number
PT1658269E
PT1658269E PT04754996T PT04754996T PT1658269E PT 1658269 E PT1658269 E PT 1658269E PT 04754996 T PT04754996 T PT 04754996T PT 04754996 T PT04754996 T PT 04754996T PT 1658269 E PT1658269 E PT 1658269E
Authority
PT
Portugal
Prior art keywords
receptor
compounds
fused compounds
subtype
inhibit vanilloid
Prior art date
Application number
PT04754996T
Other languages
English (en)
Portuguese (pt)
Inventor
M Robert Leanna
Chih-Hung Lee
Erol K Bayburt
Arthur Gomtsyan
John R Koenig
Robert Schmidt
Kirill Lukin
Gilles Chambournier
Margaret Hsu
Russel D Cink
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1658269(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/459,925 external-priority patent/US7015233B2/en
Priority claimed from US10/864,068 external-priority patent/US7375126B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT1658269E publication Critical patent/PT1658269E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT04754996T 2003-06-12 2004-06-10 Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1) PT1658269E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/459,925 US7015233B2 (en) 2003-06-12 2003-06-12 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 US7375126B2 (en) 2003-06-12 2004-06-09 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Publications (1)

Publication Number Publication Date
PT1658269E true PT1658269E (pt) 2009-01-09

Family

ID=33555102

Family Applications (2)

Application Number Title Priority Date Filing Date
PT04754996T PT1658269E (pt) 2003-06-12 2004-06-10 Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1)
PT08166079T PT2017265E (pt) 2003-06-12 2004-06-10 Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT08166079T PT2017265E (pt) 2003-06-12 2004-06-10 Compostos condensados que inibem o receptor vanilóide de subtipo 1 (vr1)

Country Status (20)

Country Link
EP (2) EP2017265B1 (enExample)
JP (2) JP4857113B2 (enExample)
KR (2) KR101138216B1 (enExample)
CN (1) CN102617464A (enExample)
AT (2) ATE411982T1 (enExample)
AU (2) AU2004247721C1 (enExample)
BR (1) BRPI0411116A (enExample)
CA (2) CA2756058A1 (enExample)
CY (2) CY1108713T1 (enExample)
DE (1) DE602004017329D1 (enExample)
DK (2) DK2017265T3 (enExample)
ES (1) ES2318308T3 (enExample)
IL (4) IL172457A (enExample)
MX (1) MXPA05013550A (enExample)
NZ (3) NZ590234A (enExample)
PL (2) PL2017265T3 (enExample)
PT (2) PT1658269E (enExample)
SI (2) SI2017265T1 (enExample)
TW (3) TWI366461B (enExample)
WO (1) WO2004111009A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
EP1931681B1 (en) 2005-10-07 2012-11-14 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
AU2006306146A1 (en) * 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009096701A2 (en) 2008-01-28 2009-08-06 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
UY32180A (es) * 2008-10-17 2010-05-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
BR112014027644A2 (pt) * 2012-05-09 2017-06-27 Bayer Cropscience Ag 5-halogenopirazol-indanil-carboxamidas
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
CA2891334C (en) 2012-11-13 2021-10-19 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
CA3022432A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536734B (en) * 2000-07-31 2003-06-11 Clariant Int Ltd Process for manufacturing a microelectronic device
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003241453A1 (en) * 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Also Published As

Publication number Publication date
TWI366461B (en) 2012-06-21
PL1658269T3 (pl) 2009-08-31
IL172457A (en) 2011-12-29
CN102617464A (zh) 2012-08-01
CA2756058A1 (en) 2004-12-23
ATE510824T1 (de) 2011-06-15
MXPA05013550A (es) 2006-04-05
AU2010257277A1 (en) 2011-01-13
JP2011153148A (ja) 2011-08-11
BRPI0411116A (pt) 2006-07-18
PT2017265E (pt) 2011-07-29
AU2004247721C1 (en) 2011-12-22
TW200509926A (en) 2005-03-16
PL2017265T3 (pl) 2011-11-30
IL215997A0 (en) 2011-12-29
IL172457A0 (en) 2006-04-10
KR101138216B1 (ko) 2012-09-05
JP2007500753A (ja) 2007-01-18
TW201300361A (zh) 2013-01-01
KR20110089464A (ko) 2011-08-08
CY1111945T1 (el) 2015-11-04
IL216046A0 (en) 2011-12-29
IL207335A0 (en) 2010-12-30
NZ543713A (en) 2009-08-28
HK1126488A1 (en) 2009-09-04
ATE411982T1 (de) 2008-11-15
TW201038269A (en) 2010-11-01
SI1658269T1 (sl) 2009-04-30
EP2017265A1 (en) 2009-01-21
TWI394569B (zh) 2013-05-01
AU2004247721B2 (en) 2011-01-20
EP1658269B1 (en) 2008-10-22
HK1093727A1 (en) 2007-03-09
JP4857113B2 (ja) 2012-01-18
KR101150324B1 (ko) 2012-06-13
KR20060058769A (ko) 2006-05-30
CY1108713T1 (el) 2014-04-09
SI2017265T1 (sl) 2011-09-30
NZ578264A (en) 2011-02-25
WO2004111009A1 (en) 2004-12-23
AU2010257277B2 (en) 2011-08-18
NZ590234A (en) 2012-07-27
DE602004017329D1 (de) 2008-12-04
DK1658269T3 (da) 2009-01-12
DK2017265T3 (da) 2011-09-19
CA2526872C (en) 2013-02-05
EP1658269A1 (en) 2006-05-24
AU2004247721A1 (en) 2004-12-23
IL207335A (en) 2012-02-29
EP2017265B1 (en) 2011-05-25
CA2526872A1 (en) 2004-12-23
ES2318308T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
IL207335A0 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
IL173269A0 (en) Compounds for inflammation and immune-related uses
AU2003259747A8 (en) Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
TW200621232A (en) Compounds for inflammation and immune-related uses
EP1072592A3 (en) 4-arylpiperidine derivatives for the treatment of pruritus
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
MY128063A (en) Aromatic heterocyclic compound as antiinflammatory agents
EP1467982B8 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
IS6275A (is) Heteróhringa efnasambönd og notkun þeirra sem mótlyf efnaskiptaglútamatviðtaka
WO2006062981A3 (en) Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
CA2369504A1 (en) Pyrazole compositions useful as inhibitors of erk
AU2002321910A1 (en) Pyrazole-derived kinase inhibitors and uses thereof
IL216455A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2003053915A3 (en) Compounds for the treatment of inflammatory disorders
WO2005040121A3 (en) Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor
WO2005056535A8 (en) 1,2,3-triazole amide derivatives as inhibitors of cytokine production
MX2007007100A (es) Benzisotiazol-1,1-dioxido que actua como antagonistas para el subtipo 1 del receptor de vanilloida (vr1) y usos de los mismos.
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.
WO2006029210A3 (en) Acyclic 1,3-diamines and uses therefor
CA2309485A1 (en) New 4-arylpiperidine derivatives for the treatment of pruritus
AU6911101A (en) Method for producing 4-bromine-aniline derivatives